Mark Jit

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/793831/publications.pdf

Version: 2024-02-01

228 papers	26,273 citations	28242 55 h-index	9579 142 g-index
285 all docs	285 docs citations	285 times ranked	32658 citing authors

#	Article	IF	Citations
1	Quantifying the Acute Care Costs of Neonatal Bacterial Sepsis and Meningitis in Mozambique and South Africa. Clinical Infectious Diseases, 2022, 74, S64-S69.	2.9	11
2	Every Country, Every Family: Time to Act for Group B Streptococcal Disease Worldwide. Clinical Infectious Diseases, 2022, 74, S1-S4.	2.9	7
3	Rapid COVID-19 vaccine rollout: immense success but challenges ahead. Lancet Infectious Diseases, The, 2022, 22, 302-304.	4.6	11
4	Optimising health and economic impacts of COVID-19 vaccine prioritisation strategies in the WHO European Region: a mathematical modelling study. Lancet Regional Health - Europe, The, 2022, 12, 100267.	3.0	24
5	A global assessment of the impact of school closure in reducing COVID-19 spread. Philosophical Transactions Series A, Mathematical, Physical, and Engineering Sciences, 2022, 380, 20210124.	1.6	13
6	The allocation of COVID-19 vaccines and antivirals against emerging SARS-CoV-2 variants of concern in East Asia and Pacific region: A modelling study. The Lancet Regional Health - Western Pacific, 2022, 21, 100389.	1.3	16
7	Regional-based within-year seasonal variations in influenza-related health outcomes across mainland China: a systematic review and spatio-temporal analysis. BMC Medicine, 2022, 20, 58.	2.3	9
8	In Elimination Settings, Measles Antibodies Wane After Vaccination but Not After Infection: A Systematic Review and Meta-Analysis. Journal of Infectious Diseases, 2022, 226, 1127-1139.	1.9	7
9	Cost-effectiveness of Respiratory Syncytial Virus Disease Prevention Strategies: Maternal Vaccine Versus Seasonal or Year-Round Monoclonal Antibody Program in Norwegian Children. Journal of Infectious Diseases, 2022, 226, S95-S101.	1.9	15
10	Measuring the effects of COVID-19-related disruption on dengue transmission in southeast Asia and Latin America: a statistical modelling study. Lancet Infectious Diseases, The, 2022, 22, 657-667.	4.6	68
11	WHO-led consensus statement on vaccine delivery costing: process, methods, and findings. BMC Medicine, 2022, 20, 88.	2.3	12
12	Long-Term Health-Related Quality of Life in Non-Hospitalized Coronavirus Disease 2019 (COVID-19) Cases With Confirmed Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection in England: Longitudinal Analysis and Cross-Sectional Comparison With Controls. Clinical Infectious Diseases, 2022, 75, e962-e973.	2.9	32
13	Differential health impact of intervention programs for time-varying disease risk: a measles vaccination modeling study. BMC Medicine, 2022, 20, 113.	2.3	4
14	Travel measures in the SARS-CoV-2 variant era need clear objectives. Lancet, The, 2022, 399, 1367-1369.	6.3	17
15	Prevalence and Determinants of Vaginal Infection With Human Papillomavirus Among Female University Students in Vietnam. In Vivo, 2022, 36, 241-250.	0.6	3
16	Dosing interval strategies for two-dose COVID-19 vaccination in 13 middle-income countries of Europe: Health impact modelling and benefit-risk analysis. Lancet Regional Health - Europe, The, 2022, 17, 100381.	3.0	15
17	Now or later: Health impacts of delaying singleâ€dose <scp>HPV</scp> vaccine implementation in a highâ€burden setting. International Journal of Cancer, 2022, 151, 1804-1809.	2.3	4
18	Group B streptococcus infection during pregnancy and infancy: estimates of regional and global burden. The Lancet Global Health, 2022, 10, e807-e819.	2.9	61

#	Article	IF	Citations
19	The impact of COVID-19 vaccination in prisons in England and Wales: a metapopulation model. BMC Public Health, 2022, 22, 1003.	1.2	4
20	COVID-19 impact on routine immunisations for vaccine-preventable diseases: Projecting the effect of different routes to recovery. Vaccine, 2022, 40, 4142-4149.	1.7	6
21	Transmission dynamics of SARS-CoV-2 in a strictly-Orthodox Jewish community in the UK. Scientific Reports, 2022, 12, .	1.6	0
22	A global agenda for older adult immunization in the COVID-19 era: A roadmap for action. Vaccine, 2021, 39, 5240-5250.	1.7	52
23	From cervical cancer elimination to eradication of vaccine-type human papillomavirus: Feasibility, public health strategies and cost-effectiveness. Preventive Medicine, 2021, 144, 106354.	1.6	12
24	Informing Global Cost-Effectiveness Thresholds Using Country Investment Decisions: Human Papillomavirus Vaccine Introductions in 2006-2018. Value in Health, 2021, 24, 61-66.	0.1	17
25	Estimating the health impact of vaccination against ten pathogens in 98 low-income and middle-income countries from 2000 to 2030: a modelling study. Lancet, The, 2021, 397, 398-408.	6.3	144
26	Effect of internationally imported cases on internal spread of COVID-19: a mathematical modelling study. Lancet Public Health, The, 2021, 6, e12-e20.	4.7	153
27	Who should be prioritized for COVID-19 vaccination in China? A descriptive study. BMC Medicine, 2021, 19, 45.	2.3	56
28	The impact of non-pharmaceutical interventions on SARS-CoV-2 transmission across 130 countries and territories. BMC Medicine, 2021, 19, 40.	2.3	257
29	Incidence and disease burden of herpes zoster in the population aged â‰¥50 years in China: Data from an integrated health care network. Journal of Infection, 2021, 82, 253-260.	1.7	38
30	Continued HPV vaccination in the face of unexpected challenges: A commentary on the rationale for an extended interval two-dose schedule. Vaccine, 2021, 39, 871-875.	1.7	5
31	Effectiveness and cost-effectiveness of eliminating cervical cancer through a tailored optimal pathway: a modeling study. BMC Medicine, 2021, 19, 62.	2.3	18
32	Challenges in ensuring global access to COVID-19 vaccines: production, affordability, allocation, and deployment. Lancet, The, 2021, 397, 1023-1034.	6.3	885
33	Association of tiered restrictions and a second lockdown with COVID-19 deaths and hospital admissions in England: a modelling study. Lancet Infectious Diseases, The, 2021, 21, 482-492.	4.6	100
34	Cost-effectiveness analysis of the nonavalent human papillomavirus vaccine for the prevention of cervical cancer in Singapore. Vaccine, 2021, 39, 2255-2263.	1.7	5
35	Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England. Science, 2021, 372, .	6.0	2,103
36	Comparison of Public Responses to Containment Measures During the Initial Outbreak and Resurgence of COVID-19 in China: Infodemiology Study. Journal of Medical Internet Research, 2021, 23, e26518.	2.1	21

#	Article	IF	Citations
37	Real-time monitoring of COVID-19 dynamics using automated trend fitting and anomaly detection. Philosophical Transactions of the Royal Society B: Biological Sciences, 2021, 376, 20200266.	1.8	12
38	The impact of childhood pneumococcal conjugate vaccine immunisation on all-cause pneumonia admissions in Hong Kong: A 14-year population-based interrupted time series analysis. Vaccine, 2021, 39, 2628-2635.	1.7	4
39	The potential for vaccination-induced herd immunity against the SARS-CoV-2 B.1.1.7 variant. Eurosurveillance, 2021, 26, .	3.9	30
40	Exploring surveillance data biases when estimating the reproduction number: with insights into subpopulation transmission of COVID-19 in England. Philosophical Transactions of the Royal Society B: Biological Sciences, 2021, 376, 20200283.	1.8	31
41	Exploring equity in health and poverty impacts of control measures for SARS-CoV-2 in six countries. BMJ Global Health, 2021, 6, e005521.	2.0	13
42	COVID-19 vaccine challenges: What have we learned so far and what remains to be done?. Health Policy, 2021, 125, 553-567.	1.4	199
43	Estimation of country-level incidence of early-onset invasive Group B Streptococcus disease in infants using Bayesian methods. PLoS Computational Biology, 2021, 17, e1009001.	1.5	3
44	Impact of COVID-19-related disruptions to measles, meningococcal A, and yellow fever vaccination in 10 countries. ELife, 2021, 10, .	2.8	54
45	Mortality, neurodevelopmental impairments, and economic outcomes after invasive group B streptococcal disease in early infancy in Denmark and the Netherlands: a national matched cohort study. The Lancet Child and Adolescent Health, 2021, 5, 398-407.	2.7	50
46	Divergent vaccination policies could fuel mistrust and hesitancy. Lancet, The, 2021, 397, 2333.	6.3	15
47	Global diarrhoea-associated mortality estimates and models in children: Recommendations for dataset and study selection. Vaccine, 2021, 39, 4391-4398.	1.7	12
48	The potential health and economic value of SARS-CoV-2 vaccination alongside physical distancing in the UK: a transmission model-based future scenario analysis and economic evaluation. Lancet Infectious Diseases, The, 2021, 21, 962-974.	4.6	117
49	Lives saved with vaccination for 10 pathogens across 112 countries in a pre-COVID-19 world. ELife, 2021, 10, .	2.8	50
50	Optimal human papillomavirus vaccination strategies to prevent cervical cancer in low-income and middle-income countries in the context of limited resources: a mathematical modelling analysis. Lancet Infectious Diseases, The, 2021, 21, 1598-1610.	4.6	34
51	Projecting contact matrices in 177 geographical regions: An update and comparison with empirical data for the COVID-19 era. PLoS Computational Biology, 2021, 17, e1009098.	1.5	115
52	Evaluating the impact of a continued maternal pertussis immunisation programme in England: A modelling study and cost-effectiveness analysis. Vaccine, 2021, 39, 4500-4509.	1.7	4
53	The CAPACITI Decision-Support Tool for National Immunization Programs. Value in Health, 2021, 24, 1150-1157.	0.1	9
54	SARS-CoV-2 infection risk during delivery of childhood vaccination campaigns: a modelling study. BMC Medicine, 2021, 19, 198.	2.3	8

#	Article	IF	Citations
55	Modeling the effect of vaccination on selection for antibiotic resistance in Streptococcus pneumonia e. Science Translational Medicine, 2021, 13, .	5.8	9
56	An Introduction to the Main Types of Economic Evaluations Used for Informing Priority Setting and Resource Allocation in Healthcare: Key Features, Uses, and Limitations. Frontiers in Public Health, 2021, 9, 722927.	1.3	49
57	Estimating the impact of reopening schools on the reproduction number of SARS-CoV-2 in England, using weekly contact survey data. BMC Medicine, 2021, 19, 233.	2.3	24
58	Antimicrobial Resistance: Is Health Technology Assessment Part of the Solution or Part of the Problem?. Value in Health, 2021, 24, 1828-1834.	0.1	22
59	Cost-effectiveness of strategies for preventing paediatric lower respiratory infections associated with respiratory syncytial virus in eight Chinese cities. Vaccine, 2021, 39, 5490-5498.	1.7	7
60	Anal human papillomavirus prevalence and risk factors among men who have sex with men in Vietnam. International Journal of Infectious Diseases, 2021, 112, 136-143.	1.5	5
61	Association of enteropathogen detection with diarrhoea by age and high versus low child mortality settings: a systematic review and meta-analysis. The Lancet Global Health, 2021, 9, e1402-e1410.	2.9	17
62	How to Prevent Vaccines Falling Victim to Their Own Success: Intertemporal Dependency of Incidence Levels on Indirect Effects in Economic Reevaluations. Value in Health, 2021, 24, 1391-1399.	0.1	1
63	HPV16 and HPV18 seropositivity and DNA detection among men who have sex with men: a cross-sectional study conducted in a sexual health clinic in London. Sexually Transmitted Infections, 2021, 97, 382-386.	0.8	2
64	Date of introduction and epidemiologic patterns of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in Mogadishu, Somalia: estimates from transmission modelling of satellite-based excess mortality data in 2020. Wellcome Open Research, 2021, 6, 255.	0.9	0
65	COVID-19 vaccination in Sindh Province, Pakistan: A modelling study of health impact and cost-effectiveness. PLoS Medicine, 2021, 18, e1003815.	3.9	33
66	Multi-country collaboration in responding to global infectious disease threats: lessons for Europe from the COVID-19 pandemic. Lancet Regional Health - Europe, The, 2021, 9, 100221.	3.0	26
67	A cross-sectional analysis of meteorological factors and SARS-CoV-2 transmission in 409 cities across 26 countries. Nature Communications, 2021, 12, 5968.	5.8	66
68	Projections of human papillomavirus (HPV) vaccination impact in Ethiopia, India, Nigeria and Pakistan: a comparative modelling study. BMJ Global Health, 2021, 6, e006940.	2.0	6
69	How can the public health impact of vaccination be estimated?. BMC Public Health, 2021, 21, 2049.	1.2	11
70	World Health Organization Expert Working Group: Recommendations for assessing morbidity associated with enteric pathogens. Vaccine, 2021, 39, 7521-7525.	1.7	16
71	Effect of evidence updates on key determinants of measles vaccination impact: a DynaMICE modelling study in ten high-burden countries. BMC Medicine, 2021, 19, 281.	2.3	9
72	Stark choices: exploring health sector costs of policy responses to COVID-19 in low-income and middle-income countries. BMJ Global Health, 2021, 6, e005759.	2.0	21

#	Article	IF	Citations
73	Models of COVID-19 vaccine prioritisation: a systematic literature search and narrative review. BMC Medicine, 2021, 19, 318.	2.3	20
74	The effect of time since measles vaccination and age at first dose on measles vaccine effectiveness â€“ A systematic review. Vaccine, 2020, 38, 460-469.	1.7	30
75	Effect of Pediatric Influenza Vaccination on Antibiotic Resistance, England and Wales. Emerging Infectious Diseases, 2020, 26, 138-142.	2.0	7
76	Systematic Review on the Acute Cost-of-illness of Sepsis and Meningitis in Neonates and Infants. Pediatric Infectious Disease Journal, 2020, 39, 35-40.	1.1	14
77	The impact of COVID-19 control measures on social contacts and transmission in Kenyan informal settlements. BMC Medicine, 2020, 18, 316.	2.3	88
78	Response strategies for COVID-19 epidemics in African settings: a mathematical modelling study. BMC Medicine, 2020, 18, 324.	2.3	66
79	Reconstructing the early global dynamics of under-ascertained COVID-19 cases and infections. BMC Medicine, 2020, 18, 332.	2.3	129
80	Caregiver and service provider vaccine confidence following the Changchun Changsheng vaccine incident in China: A cross-sectional mixed methods study. Vaccine, 2020, 38, 6882-6888.	1.7	17
81	Access and Unmet Needs of Orphan Drugs in 194 Countries and 6 Areas: A Global Policy Review With Content Analysis. Value in Health, 2020, 23, 1580-1591.	0.1	41
82	A review of the costs of delivering maternal immunisation during pregnancy. Vaccine, 2020, 38, 6199-6204.	1.7	9
83	Ensuring access and affordability through COVID-19 vaccine research and development investments: A proposal for the options market for vaccines. Vaccine, 2020, 38, 6075-6077.	1.7	17
84	Comparative Distributional Impact of Routine Immunization and Supplementary Immunization Activities in Delivery of Measles Vaccine in Low- and Middle-Income Countries. Value in Health, 2020, 23, 891-897.	0.1	11
85	Routine childhood immunisation during the COVID-19 pandemic in Africa: a benefitâ€“risk analysis of health benefits versus excess risk of SARS-CoV-2 infection. The Lancet Global Health, 2020, 8, e1264-e1272.	2.9	265
86	Effects of non-pharmaceutical interventions on COVID-19 cases, deaths, and demand for hospital services in the UK: a modelling study. Lancet Public Health, The, 2020, 5, e375-e385.	4.7	730
87	The impact of maternal RSV vaccine to protect infants in Gavi-supported countries: Estimates from two models. Vaccine, 2020, 38, 5139-5147.	1.7	12
88	Assessing the value of human papillomavirus vaccination in Gavi-eligible low-income and middle-income countries. BMJ Global Health, 2020, 5, e003006.	2.0	14
89	The effect of travel restrictions on the geographical spread of COVID-19 between large cities in China: a modelling study. BMC Medicine, 2020, 18, 259.	2.3	28
90	Mapping the cryptic spread of the 2015â€“2016 global Zika virus epidemic. BMC Medicine, 2020, 18, 399.	2.3	3

#	Article	IF	Citations
91	The role of vaccines in combating antimicrobial resistance. , 2020, , 181-206.		2
92	Effectiveness of isolation, testing, contact tracing, and physical distancing on reducing transmission of SARS-CoV-2 in different settings: a mathematical modelling study. Lancet Infectious Diseases, The, 2020, 20, 1151-1160.	4.6	710
93	Global, regional, and national estimates of the population at increased risk of severe COVID-19 due to underlying health conditions in 2020: a modelling study. The Lancet Global Health, 2020, 8, e1003-e1017.	2.9	760
94	Age-dependent effects in the transmission and control of COVID-19 epidemics. Nature Medicine, 2020, 26, 1205-1211.	15.2	1,404
95	Cervical screening: ESGO-EFC position paper of the European Society of Gynaecologic Oncology (ESGO) and the European Federation of Colposcopy (EFC). British Journal of Cancer, 2020, 123, 510-517.	2.9	74
96	Early dynamics of transmission and control of COVID-19: a mathematical modelling study. Lancet Infectious Diseases, The, 2020, 20, 553-558.	4.6	1,999
97	Quantifying the economic cost of antibiotic resistance and the impact of related interventions: rapid methodological review, conceptual framework and recommendations for future studies. BMC Medicine, 2020, 18, 38.	2.3	52
98	The effect of control strategies to reduce social mixing on outcomes of the COVID-19 epidemic in Wuhan, China: a modelling study. Lancet Public Health, The, 2020, 5, e261-e270.	4.7	1,600
99	Optimizing Benefits of Testing Key Workers for Infection with SARS-CoV-2: A Mathematical Modeling Analysis. Clinical Infectious Diseases, 2020, 71, 3196-3203.	2.9	6
100	Effects of updated demography, disability weights, and cervical cancer burden on estimates of human papillomavirus vaccination impact at the global, regional, and national levels: a PRIME modelling study. The Lancet Global Health, 2020, 8, e536-e544.	2.9	39
101	Feasibility of controlling COVID-19 outbreaks by isolation of cases and contacts. The Lancet Global Health, 2020, 8, e488-e496.	2.9	2,067
102	The impact of vaccination on gender equity: conceptual framework and human papillomavirus (HPV) vaccine case study. International Journal for Equity in Health, 2020, 19, 10.	1.5	11
103	Shaping meeting to explore the value of a coordinated work plan for epidemic and pandemic influenza vaccine preparedness. Vaccine, 2020, 38, 3179-3183.	1.7	3
104	Meeting Report: WHO Workshop on modelling global mortality and aetiology estimates of enteric pathogens in children under five. Cape Town, 28â€“29th November 2018. Vaccine, 2020, 38, 4792-4800.	1.7	16
105	Cost-effectiveness of introducing national seasonal influenza vaccination for adults aged 60Âyears and above in mainland China: a modelling analysis. BMC Medicine, 2020, 18, 90.	2.3	24
106	Health and economic burden of respiratory syncytial virus (RSV) disease and the cost-effectiveness of potential interventions against RSV among children under 5Âyears in 72 Gavi-eligible countries. BMC Medicine, 2020, 18, 82.	2.3	59
107	Quantifying long-term health and economic outcomes for survivors of group B Streptococcus invasive disease in infancy: protocol of a multi-country study in Argentina, India, Kenya, Mozambique and South Africa. Gates Open Research, 2020, 4, 138.	2.0	6
108	Impact of HPV vaccination and cervical screening on cervical cancer elimination: a comparative modelling analysis in 78 low-income and lower-middle-income countries. Lancet, The, 2020, 395, 575-590.	6.3	421

#	Article	IF	Citations
109	Estimating number of cases and spread of coronavirus disease (COVID-19) using critical care admissions, United Kingdom, February to March 2020. Eurosurveillance, 2020, 25, .	3.9	34
110	Imiquimod versus podophyllotoxin, with and without human papillomavirus vaccine, for anogenital warts: the HIPvac factorial RCT. Health Technology Assessment, 2020, 24, 1-86.	1.3	16
111	Guidelines for multi-model comparisons of the impact of infectious disease interventions. BMC Medicine, 2019, 17, 163.	2.3	39
112	The global impact and cost-effectiveness of a melioidosis vaccine. BMC Medicine, 2019, 17, 129.	2.3	11
113	Adjusting for Inflation and Currency Changes Within Health Economic Studies. Value in Health, 2019, 22, 1026-1032.	0.1	151
114	Mortality reduction benefits and intussusception risks of rotavirus vaccination in 135 low-income and middle-income countries: a modelling analysis of current and alternative schedules. The Lancet Global Health, 2019, 7, e1541-e1552.	2.9	46
115	HPV-FRAME: A consensus statement and quality framework for modelled evaluations of HPV-related cancer control. Papillomavirus Research (Amsterdam, Netherlands), 2019, 8, 100184.	4.5	41
116	Combining serological and contact data to derive target immunity levels for achieving and maintaining measles elimination. BMC Medicine, 2019, 17, 180.	2.3	57
117	Strengthening national vaccine decision-making: Assessing the impact of SIVAC Initiative support on national immunisation technical advisory group (NITAG) functionality in 77 low and middle-income countries. Vaccine, 2019, 37, 430-434.	1.7	9
118	Efficacy of live oral rotavirus vaccines by duration of follow-up: a meta-regression of randomised controlled trials. Lancet Infectious Diseases, The, 2019, 19, 717-727.	4.6	81
119	A Scoping Review of Investment Cases for Vaccines and Immunization Programs. Value in Health, 2019, 22, 942-952.	0.1	11
120	Clinical impact and cost-effectiveness of primary cytology versus human papillomavirus testing for cervical cancer screening in England. International Journal of Gynecological Cancer, 2019, 29, 669-675.	1.2	16
121	Quantifying the public's view on social value judgments in vaccine decision-making: A discrete choice experiment. Social Science and Medicine, 2019, 228, 181-193.	1.8	23
122	Estimates of case-fatality ratios of measles in low-income and middle-income countries: a systematic review and modelling analysis. The Lancet Global Health, 2019, 7, e472-e481.	2.9	68
123	Global Case-Fatality Rates in Pediatric Severe Sepsis and Septic Shock. JAMA Pediatrics, 2019, 173, 352.	3.3	152
124	Within-host dynamics shape antibiotic resistance in commensal bacteria. Nature Ecology and Evolution, 2019, 3, 440-449.	3.4	76
125	The role of pneumococcal conjugate vaccination in reducing pneumonia mortality. The Lancet Global Health, 2019, 7, e173-e174.	2.9	0
126	O06.4â€…Efficacy and cost-effectiveness of qHPV vaccine with imiquimod or podophyllotoxin for patients with anogenital warts (HIPvac). , 2019, , .		0

#	Article	IF	Citations
127	Mathematical modelling for antibiotic resistance control policy: do we know enough?. BMC Infectious Diseases, 2019, 19, 1011.	1.3	37
128	Patterns of human social contact and contact with animals in Shanghai, China. Scientific Reports, 2019, 9, 15141.	1.6	61
129	Determinants of methicillin-resistant Staphylococcus aureus (MRSA) prevalence in the Asia-Pacific region: A systematic review and meta-analysis. Journal of Global Antimicrobial Resistance, 2019, 16, 17-27.	0.9	32
130	Effect and cost-effectiveness of pneumococcal conjugate vaccination: a global modelling analysis. The Lancet Global Health, 2019, 7, e58-e67.	2.9	72
131	Systematic review and evidence synthesis of non-cervical human papillomavirus-related disease health system costs and quality of life estimates. Sexually Transmitted Infections, 2019, 95, 28-35.	0.8	7
132	Mortality in Pediatric Acute Respiratory Distress Syndrome: A Systematic Review and Meta-Analysis. Journal of Intensive Care Medicine, 2019, 34, 563-571.	1.3	76
133	Potential lives saved in 73 countries by adopting multiâ€cohort vaccination of 9â€“14â€yearâ€old girls against human papillomavirus. International Journal of Cancer, 2018, 143, 317-323.	2.3	15
134	Estimating the Hospital Burden of Norovirus-Associated Gastroenteritis in England and Its Opportunity Costs for Nonadmitted Patients. Clinical Infectious Diseases, 2018, 67, 693-700.	2.9	28
135	Thresholds for decision-making: informing the cost-effectiveness and affordability of rotavirus vaccines in Malaysia. Health Policy and Planning, 2018, 33, 204-214.	1.0	14
136	Impact of measles supplementary immunization activities on reaching children missed by routine programs. Vaccine, 2018, 36, 170-178.	1.7	56
137	The need for sustainability and alignment of future support for National Immunization Technical Advisory Groups (NITAGs) in low and middle-income countries. Human Vaccines and Immunotherapeutics, 2018, 14, 1539-1541.	1.4	17
138	A bibliometric analysis of systematic reviews on vaccines and immunisation. Vaccine, 2018, 36, 2254-2261.	1.7	18
139	Estimating burden of influenzaâ€associated influenzaâ€like illness and severe acute respiratory infection at public healthcare facilities in Romania during the 2011/12â€2015/16 influenza seasons. Influenza and Other Respiratory Viruses, 2018, 12, 183-192.	1.5	14
140	Estimating the opportunity costs of bedâ€days. Health Economics (United Kingdom), 2018, 27, 592-605.	0.8	31
141	Capturing Budget Impact Considerations Within Economic Evaluations: A Systematic Review of Economic Evaluations of Rotavirus Vaccine in Low- and Middle-Income Countries and a Proposed Assessment Framework. Pharmacoeconomics, 2018, 36, 79-90.	1.7	13
142	Use of mathematical modelling to assess the impact of vaccines on antibiotic resistance. Lancet Infectious Diseases, The, 2018, 18, e204-e213.	4.6	63
143	MCDA from a health economics perspective: opportunities and pitfalls of extending economic evaluation to incorporate broader outcomes. Cost Effectiveness and Resource Allocation, 2018, 16, 45.	0.6	10
144	Human papillomavirus infection: protocol for a randomised controlled trial of imiquimod cream (5%) versus podophyllotoxin cream (0.15%), in combination with quadrivalent human papillomavirus or control vaccination in the treatment and prevention of recurrence of anogenital warts (HIPvac) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 52	1.4	19

#	Article	IF	Citations
145	Determining environmental and anthropogenic factors which explain the global distribution of Aedes aegypti and Ae. albopictus. BMJ Global Health, 2018, 3, e000801.	2.0	64
146	Toward economic evaluation of the value of vaccines and other health technologies in addressing AMR. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, 12911-12919.	3.3	107
147	Economic Analysis of Vaccination Programs: An ISPOR Good Practices for Outcomes Research Task Force Report. Value in Health, 2018, 21, 1133-1149.	0.1	94
148	Cost-benefit analysis of vaccination: a comparative analysis of eight approaches for valuing changes to mortality and morbidity risks. BMC Medicine, 2018, 16, 139.	2.3	24
149	Human papillomavirus vaccine effectiveness by number of doses: Systematic review of data from national immunization programs. Vaccine, 2018, 36, 4806-4815.	1.7	68
150	Model Comparisons of the Effectiveness and Cost-Effectiveness of Vaccination: A Systematic Review of the Literature. Value in Health, 2018, 21, 1250-1258.	0.1	21
151	The Equity Impact Vaccines May Have On Averting Deaths And Medical Impoverishment In Developing Countries. Health Affairs, 2018, 37, 316-324.	2.5	57
152	Simultaneously characterizing the comparative economics of routine female adolescent nonavalent human papillomavirus (HPV) vaccination and assortativity of sexual mixing in Hong Kong Chinese: a modeling analysis. BMC Medicine, 2018, 16, 127.	2.3	14
153	Understanding differences in cervical cancer incidence in Western Europe: comparing Portugal and England. European Journal of Public Health, 2018, 28, 343-347.	0.1	11
154	Impact and cost-effectiveness of selective human papillomavirus vaccination of men who have sex with men. Clinical Infectious Diseases, 2017, 64, ciw845.	2.9	46
155	Cost-effectiveness of 13-valent pneumococcal conjugate vaccination in Mongolia. Vaccine, 2017, 35, 1055-1063.	1.7	17
156	Seropositivity to non-vaccine incorporated genotypes induced by the bivalent and quadrivalent HPV vaccines: A systematic review and meta-analysis. Vaccine, 2017, 35, 3922-3929.	1.7	21
157	Social contact patterns relevant to the spread of respiratory infectious diseases in Hong Kong. Scientific Reports, 2017, 7, 7974.	1.6	107
158	Burden of paediatric respiratory syncytial virus disease and potential effect of different immunisation strategies: a modelling and cost-effectiveness analysis for England. Lancet Public Health, The, 2017, 2, e367-e374.	4.7	72
159	Cervical cancer treatment costs and cost-effectiveness analysis of human papillomavirus vaccination in Vietnam: a PRIME modeling study. BMC Health Services Research, 2017, 17, 353.	0.9	29
160	Mini-review: Can non-human leucocyte antigen genes determine susceptibility to severe dengue syndromes?. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2017, 111, 384-392.	0.7	4
161	Projecting social contact matrices in 152 countries using contact surveys and demographic data. PLoS Computational Biology, 2017, 13, e1005697.	1.5	666
162	Characterizing measles transmission in India: a dynamic modeling study using verbal autopsy data. BMC Medicine, 2017, 15, 151.	2.3	5

#	Article	IF	Citations
163	Adding interventions to mass measles vaccinations in India. Bulletin of the World Health Organization, 2016, 94, 718-727.	1.5	3
164	The Long-Term Safety, Public Health Impact, and Cost-Effectiveness of Routine Vaccination with a Recombinant, Live-Attenuated Dengue Vaccine (Dengvaxia): A Model Comparison Study. PLoS Medicine, 2016, 13, e1002181.	3.9	178
165	Seasonal influenza vaccination delivery through community pharmacists in England: evaluation of the London pilot. BMJ Open, 2016, 6, e009739.	0.8	34
166	Population-level impact, herd immunity, and elimination after human papillomavirus vaccination: a systematic review and meta-analysis of predictions from transmission-dynamic models. Lancet Public Health, The, 2016, 1, e8-e17.	4.7	210
167	The economic burden of dengue: no longer invisible or unavoidable. Lancet Infectious Diseases, The, 2016, 16, 873-874.	4.6	4
168	Clustering of contacts relevant to the spread of infectious disease. Epidemics, 2016, 17, 1-9.	1.5	17
169	Methodological Challenges to Economic Evaluations of Vaccines: Is a Common Approach Still Possible?. Applied Health Economics and Health Policy, 2016, 14, 245-252.	1.0	32
170	Rotavirus vaccines contribute towards universal health coverage in a mixed publicâ€“private healthcare system. Tropical Medicine and International Health, 2016, 21, 1458-1467.	1.0	4
171	Assessing dengue vaccination impact: Model challenges and future directions. Vaccine, 2016, 34, 4461-4465.	1.7	17
172	The projected effectiveness of Clostridium difficile vaccination as part of an integrated infection control strategy. Vaccine, 2016, 34, 5562-5570.	1.7	17
173	Public health impact and cost-effectiveness of the RTS,S/AS01 malaria vaccine: a systematic comparison of predictions from four mathematical models. Lancet, The, 2016, 387, 367-375.	6.3	154
174	Current Global Pricing For Human Papillomavirus Vaccines Brings The Greatest Economic Benefits To Rich Countries. Health Affairs, 2016, 35, 227-234.	2.5	15
175	Methods for Health Economic Evaluation of Vaccines and Immunization Decision Frameworks: A Consensus Framework from a European Vaccine Economics Community. Pharmacoeconomics, 2016, 34, 227-244.	1.7	97
176	Modeling the impact of rubella vaccination in Vietnam. Human Vaccines and Immunotherapeutics, 2016, 12, 150-158.	1.4	13
177	Building a new communication paradigm: Can we influence influenza perception?. Vaccine, 2015, 33, 7044-7046.	1.7	3
178	The broader economic impact of vaccination: reviewing and appraising the strength of evidence. BMC Medicine, 2015, 13, 209.	2.3	106
179	The economic burden of influenza-associated outpatient visits and hospitalizations in China: a retrospective survey. Infectious Diseases of Poverty, 2015, 4, 44.	1.5	48
180	Estimating costs of care for meningitis infections in low- and middle-income countries. Vaccine, 2015, 33, A240-A247.	1.7	27

#	Article	IF	Citations
181	Systematic review of model-based cervical screening evaluations. BMC Cancer, 2015, 15, 334.	1.1	36
182	Stakeholdersâ€™ perception on including broader economic impact of vaccines in economic evaluations in low and middle income countries: a mixed methods study. BMC Public Health, 2015, 15, 356.	1.2	19
183	High-dose influenza vaccines make economic sense for older people. Lancet Infectious Diseases, The, 2015, 15, 1372-1373.	4.6	0
184	Controlling measles using supplemental immunization activities: A mathematical model to inform optimal policy. Vaccine, 2015, 33, 1291-1296.	1.7	64
185	Comparison of two dose and three dose human papillomavirus vaccine schedules: cost effectiveness analysis based on transmission model. BMJ, The, 2015, 350, g7584-g7584.	3.0	62
186	Discounting in the evaluation of the cost-effectiveness of a vaccination programme: A critical review. Vaccine, 2015, 33, 3788-3794.	1.7	51
187	Oral human papillomavirus (HPV) infection in men who have sex with men: prevalence and lack of anogenital concordance: TableÂ1. Sexually Transmitted Infections, 2015, 91, 284-286.	0.8	42
188	Quantifying Parameter and Structural Uncertainty of Dynamic Disease Transmission Models Using MCMC. Medical Decision Making, 2015, 35, 633-647.	1.2	13
189	Targeted vaccination in healthy school children â€“ Can primary school vaccination alone control influenza?. Vaccine, 2015, 33, 5415-5424.	1.7	17
190	A systematic review of the social and economic burden of influenza in low- and middle-income countries. Vaccine, 2015, 33, 6537-6544.	1.7	91
191	Systematic review of economic evaluations of vaccination programs in mainland China: Are they sufficient to inform decision making?. Vaccine, 2015, 33, 6164-6172.	1.7	20
192	Thirty years of vaccination in Vietnam: Impact and cost-effectiveness of the national Expanded Programme on Immunization. Vaccine, 2015, 33, A233-A239.	1.7	27
193	Fewer than three doses of HPV vaccine. Lancet Oncology, The, 2015, 16, e423-e424.	5.1	5
194	Household Catastrophic Healthcare Expenditure and Impoverishment Due to Rotavirus Gastroenteritis Requiring Hospitalization in Malaysia. PLoS ONE, 2015, 10, e0125878.	1.1	33
195	Burden of Severe Pneumonia, Pneumococcal Pneumonia and Pneumonia Deaths in Indian States: Modelling Based Estimates. PLoS ONE, 2015, 10, e0129191.	1.1	50
196	Nosocomial Transmission of C. difficile in English Hospitals from Patients with Symptomatic Infection. PLoS ONE, 2014, 9, e99860.	1.1	4
197	Key issues and challenges in estimating the impact and cost-effectiveness of quadrivalent influenza vaccination. Expert Review of Pharmacoeconomics and Outcomes Research, 2014, 14, 425-435.	0.7	14
198	The burden of influenza in England by age and clinical risk group: A statistical analysis to inform vaccine policy. Journal of Infection, 2014, 68, 363-371.	1.7	199

#	Article	IF	Citations
199	Comparing the cost-effectiveness of two- and three-dose schedules of human papillomavirus vaccination: A transmission-dynamic modelling study. Vaccine, 2014, 32, 5845-5853.	1.7	49
200	Two-dose strategies for human papillomavirus vaccination: How well do they need to protect?. Vaccine, 2014, 32, 3237-3242.	1.7	21
201	Evaluating the potential risks and benefits of infant rotavirus vaccination in England. Vaccine, 2014, 32, 3604-3610.	1.7	31
202	Reassessing the value of vaccines. The Lancet Global Health, 2014, 2, e251-e252.	2.9	49
203	Cost-effectiveness of female human papillomavirus vaccination in 179 countries: a PRIME modelling study. The Lancet Global Health, 2014, 2, e406-e414.	2.9	194
204	Efficacy and effectiveness of seasonal and pandemic A (H1N1) 2009 influenza vaccines in low and middle income countries: A systematic review and meta-analysis. Vaccine, 2013, 31, 5168-5177.	1.7	41
205	Acceptability and uptake of female adolescent HPV vaccination in Hong Kong: A survey of mothers and adolescents. Vaccine, 2013, 32, 78-84.	1.7	51
206	Cost-effectiveness of human papillomavirus vaccination in low and middle income countries: A systematic review. Vaccine, 2013, 31, 3786-3804.	1.7	91
207	Influenza vaccines in low and middle income countries. Human Vaccines and Immunotherapeutics, 2013, 9, 1500-1511.	1.4	50
208	Key issues for estimating the impact and cost-effectiveness of seasonal influenza vaccination strategies. Human Vaccines and Immunotherapeutics, 2013, 9, 834-840.	1.4	35
209	Systematic review of studies evaluating the broader economic impact of vaccination in low and middle income countries. BMC Public Health, 2012, 12, 878.	1.2	96
210	Cross-protective efficacy of two human papillomavirus vaccines: a systematic review and meta-analysis. Lancet Infectious Diseases, The, 2012, 12, 781-789.	4.6	343
211	Enzymes provide demographers with food for thought. ELife, 2012, 1, e00340.	2.8	0
212	Modelling the Epidemiology of Infectious Diseases for Decision Analysis. Pharmacoeconomics, 2011, 29, 371-386.	1.7	95
213	What types of contacts are important for the spread of infections? Using contact survey data to explore European mixing patterns. Epidemics, 2011, 3, 143-151.	1.5	123
214	Comparing bivalent and quadrivalent human papillomavirus vaccines: economic evaluation based on transmission model. BMJ: British Medical Journal, 2011, 343, d5775-d5775.	2.4	102
215	The Impact of Pandemic Influenza H1N1 on Health-Related Quality of Life: A Prospective Population-Based Study. PLoS ONE, 2011, 6, e17030.	1.1	75
216	7-Valent Pneumococcal Conjugate Vaccination in England and Wales: Is It Still Beneficial Despite High Levels of Serotype Replacement?. PLoS ONE, 2011, 6, e26190.	1.1	52

#	Article	IF	Citations
217	Predicting the lifeâ€time benefit of schoolâ€based smoking prevention programmes. Addiction, 2010, 105, 1109-1116.	1.7	11
218	Transmission dynamic modelling of the impact of human papillomavirus vaccination in the United Kingdom. Vaccine, 2010, 28, 4091-4102.	1.7	92
219	Vaccination against pandemic influenza A/H1N1v in England: A real-time economic evaluation. Vaccine, 2010, 28, 2370-2384.	1.7	160
220	The cost-effectiveness of vaccinating pregnant women against seasonal influenza in England and Wales. Vaccine, 2010, 29, 115-122.	1.7	44
221	The cost-effectiveness of rotavirus vaccination: Comparative analyses for five European countries and transferability in Europe. Vaccine, 2009, 27, 6121-6128.	1.7	88
222	Cost of Treatment and QALYs Lost Due to Genital Warts: Data for the Economic Evaluation of HPV Vaccines in the United Kingdom. Sexually Transmitted Diseases, 2009, 36, 515-521.	0.8	31
223	Economic evaluation of human papillomavirus vaccination in the United Kingdom. BMJ: British Medical Journal, 2008, 337, a769-a769.	2.4	245
224	Social Contacts and Mixing Patterns Relevant to the Spread of Infectious Diseases. PLoS Medicine, 2008, 5, e74.	3.9	2,355
225	The Full Value of Vaccine Assessments (FVVA): A Framework to Assess and Communicate the Value of Vaccines for Investment and Introduction Decision Making. SSRN Electronic Journal, 0, , .	0.4	21
226	Integrating economic and health evidence to inform Covid-19 policy in low- and middle- income countries. Wellcome Open Research, 0, 5, 272.	0.9	4
227	Designing a multi-layered surveillance approach to detecting SARS-CoV-2: A modelling study. Wellcome Open Research, 0, 5, 218.	0.9	0
228	Date of introduction and epidemiologic patterns of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in Mogadishu, Somalia: estimates from transmission modelling of satellite-based excess mortality data in 2020. Wellcome Open Research, 0, 6, 255.	0.9	0